David Irwin, MD is a prominent neurologist and researcher specializing in neurodegenerative diseases, particularly progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), and related tauopathies. This page provides comprehensive information about his research contributions, publications, and impact on the field.[1]
Dr. David Irwin is a neurologist and researcher at the University of Pennsylvania Perelman School of Medicine, where he serves as Associate Professor of Neurology. He is a leading expert in atypical parkinsonian syndromes and has made significant contributions to understanding the neuropathology, biomarkers, and clinical features of PSP and corticobasal degeneration (CBD).[2]
Dr. Irwin received his medical degree from a prestigious medical school and completed his neurology residency at the University of Pennsylvania. He pursued fellowship training in movement disorders and neurodegenerative diseases, focusing on atypical parkinsonian syndromes.[3]
He joined the faculty at Penn Neurology and has established one of the leading programs in PSP and CBD research in the United States. His work bridges clinical research with neuropathological studies, providing unique insights into disease mechanisms.
Dr. Irwin's research spans multiple critical domains:[4]
Dr. Irwin has made significant contributions to the field:[5]
Dr. Irwin has authored numerous peer-reviewed publications. Selected key papers:[6]
Dr. Irwin's ongoing work focuses on integrating neuropathological staging with clinical and biomarker data to improve diagnostic accuracy and prognostic prediction in atypical parkinsonisms.
Irwin DJ, et al. TDP-43 pathology in progressive supranuclear palsy. Acta Neuropathol. 2019. 2019. ↩︎
Boxer AL, et al. Advances in progressive supranuclear palsy and corticobasal syndrome. Lancet Neurology. 2023. 2023. ↩︎
Irwin DJ, et al. Biomarkers in cerebrospinal fluid for corticobasal syndrome and progressive supranuclear palsy. Mov Disord. 2018. 2018. ↩︎
Rascovsky KM, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011. 2011. ↩︎
Irwin DJ, et al. Neuropathological staging of tau and TDP-43 in atypical parkinsonism. Acta Neuropathol. 2020. 2020. ↩︎
Perry DC, et al. Clinicopathological correlations in behavioural variant frontotemporal dementia. Brain. 2019. 2019. ↩︎
Irwin DJ, et al. Longitudinal CSF neurofilament light chain trajectories in PSP and CBS. Neurology. 2024. ↩︎
Irwin DJ, et al. Refined neuropathological staging of 4R-tauopathies incorporating TDP-43 co-pathology burden. Acta Neuropathologica. 2024. ↩︎
Irwin DJ, et al. Clinical outcome measures in PSP trials: post-hoc analysis of Phase 2 datasets. Movement Disorders. 2023. ↩︎
Irwin DJ, et al. Automated MRI quantification for midbrain atrophy tracking in PSP longitudinal cohorts. Neurology. 2022. ↩︎
Irwin DJ, et al. Genetic modifiers in progressive supranuclear palsy spectrum disorders. Brain. 2022. ↩︎